Cheap SS­RI drug proves suc­cess­ful in re­duc­ing Covid-re­lat­ed hos­pi­tal­iza­tion times in large tri­al

An­oth­er weapon against Covid-19 could be made more promi­nent as re­sults from a large, place­bo-con­trolled tri­al pub­lished in the Lancet on Wednes­day evening pro­vide com­pelling ev­i­dence that the cheap SS­RI flu­vox­am­ine may re­duce Covid-re­lat­ed hos­pi­tal­iza­tion times.

Of the 741 par­tic­i­pants who re­ceived flu­vox­am­ine in the tri­al in Brazil, 79, or 10.6%, re­quired an ex­tend­ed stay for more than six hours in an emer­gency set­ting or hos­pi­tal­iza­tion, com­pared to 119 out of the 756 (15.7%) par­tic­i­pants who re­ceived place­bo.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.